|Articles|May 6, 2022

Pharmaceutical Brand Values Surge

Author(s)Pharmaceutical Executive Editorial Staff

In the wake of the COVID-19 pandemic, pharmaceutical brand names across the world have surged in value as they have become household names globally, according to a new report from leading brand valuation consultancy Brand Finance.

Every year, Brand Finance puts 5,000 of the world’s biggest brands to the test, and publishes around 100 reports, ranking brands across all sectors and countries. The pharmaceutical industry’s top 25 most valuable and strongest brands in the world are included in the annual Brand Finance Pharma 25 rankings found here.

View the full Brand Finance Pharma 25 report here

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Pharmaceutical Brand Values Surge

Related Content

Pharma M&A Roundup: Incyte to Acquire Vega Therapeutics, Galmed Pharmaceuticals to Acquire Colospan, Johnson & Johnson Acquires Firefly Bio

Using a Customer-Based Process to Synchronize Sales & Marketing Organizations in Pharma

Why Branding is Pharma’s Most Undervalued Asset

The New Era of U.S. Pharmaceutical Pricing: From Policy Upheaval to Strategic Adaptation

Data and Trust

Trending on PharmExec

Beyond JAK Inhibitors: Biologics Signal a New Era in Alopecia Areata

Pharma M&A Roundup: Incyte to Acquire Vega Therapeutics, Galmed Pharmaceuticals to Acquire Colospan, Johnson & Johnson Acquires Firefly Bio

Chai Discovery Enters License Agreement with Pfizer to Accelerate Drug Discovery with AI

U.S. Supreme Court Unanimously Votes in Favor of Hikma in Case Against Amarin: Report

Roche Enters $2.3 Billion Global Collaboration with Nurix Therapeutics to Co-Develop and Co-Commercialize Bexobrutideg